Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients
Abstract Background We have previously shown that glycine increases fat‐free mass in chronic haemodialysis patients with features of malnutrition as compared with branched‐chain amino acids (BCAAs). This multicentre randomized double‐blind crossover study evaluates the impact of these amino acids on...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | Journal of Cachexia, Sarcopenia and Muscle |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jcsm.12781 |
| _version_ | 1797205392497836032 |
|---|---|
| author | Laurence Genton Menno Pruijm Daniel Teta Isabelle Bassi Patrice D. Cani Nadia Gaïa François R. Herrmann Nicola Marangon Julie Mareschal Giulio G. Muccioli Catherine Stoermann Francesco Suriano Arlene Wurzner‐Ghajarzadeh Vladimir Lazarevic Jacques Schrenzel |
| author_facet | Laurence Genton Menno Pruijm Daniel Teta Isabelle Bassi Patrice D. Cani Nadia Gaïa François R. Herrmann Nicola Marangon Julie Mareschal Giulio G. Muccioli Catherine Stoermann Francesco Suriano Arlene Wurzner‐Ghajarzadeh Vladimir Lazarevic Jacques Schrenzel |
| author_sort | Laurence Genton |
| collection | DOAJ |
| description | Abstract Background We have previously shown that glycine increases fat‐free mass in chronic haemodialysis patients with features of malnutrition as compared with branched‐chain amino acids (BCAAs). This multicentre randomized double‐blind crossover study evaluates the impact of these amino acids on the gut barrier and microbiota. Methods Haemodialysis patients were included if they had plasma albumin <38 g/L or weight loss >5% of dry body weight, and daily dietary intakes <30 kcal/kg and <1 g protein/kg. They consumed glycine or BCAA (7 g twice daily) for 4 months and underwent a 1 month washout period, before crossover of supplementations. Faecal microbiota (16S rRNA gene sequencing) and immunoglobulin A (IgA), serum levels of cytokines, surrogate markers of intestinal permeability, appetite mediators, and endocannabinoids were obtained at the start and end of each supplementation. Supplementations were compared by multiple mixed linear regression models, adjusted for age, sex, month of supplementation (0 and 4 in each period), and period (Period 1: first 4 months; Period 2: last 4 months). Microbiota comparisons were performed using principal coordinate analysis and permutational multivariate analysis of variance, Shannon diversity index estimate and analysis of composition of microbiomes analysis, and Wilcoxon tests. Results We analysed 27 patients compliant to the supplementations. Multiple mixed linear regression models were significant only for interleukin‐6 (P = 0.002), glucagon‐like peptide 1 (P = 0.028), cholecystokinin (P = 0.021), and peptide YY (P = 0.002), but not for the other outcomes. The significant models did not show any impact of the type of supplementation (P < 0.05 in all models). Principal coordinate analysis and permutational multivariate analysis of variance (P = 0.0001) showed strong microbiota clustering by subject, but no effect of the amino acids. Bacterial alpha diversity and zero‐radius operational taxonomic unit richness remained stable, whatever the supplementation. Lacticaseibacillus paracasei (0.030; Q1–Q3 0.008–0.078 vs. 0.004; Q1–Q3 0.001–0.070) and Bifidobacterium dentium (0.0247; Q1–Q3 0.002–0.191 vs. 0.003; Q1–Q3 0.001–0.086) significantly decreased with the BCAA supplementation. Conclusions The BCAA and glycine supplementations had no impact on the serum levels of cytokines, appetite mediators, intestinal permeability, endocannabinoids, or faecal IgA. Overall faecal microbiota composition and microbial diversity did not change with the glycine or BCAA supplementation but decreased the abundance of L. paracasei and B. dentium. |
| first_indexed | 2024-04-24T08:50:24Z |
| format | Article |
| id | doaj.art-d7d2300fefa94c4c836ee888f2ae612e |
| institution | Directory Open Access Journal |
| issn | 2190-5991 2190-6009 |
| language | English |
| last_indexed | 2024-04-24T08:50:24Z |
| publishDate | 2021-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Cachexia, Sarcopenia and Muscle |
| spelling | doaj.art-d7d2300fefa94c4c836ee888f2ae612e2024-04-16T12:28:15ZengWileyJournal of Cachexia, Sarcopenia and Muscle2190-59912190-60092021-12-011261527153910.1002/jcsm.12781Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patientsLaurence Genton0Menno Pruijm1Daniel Teta2Isabelle Bassi3Patrice D. Cani4Nadia Gaïa5François R. Herrmann6Nicola Marangon7Julie Mareschal8Giulio G. Muccioli9Catherine Stoermann10Francesco Suriano11Arlene Wurzner‐Ghajarzadeh12Vladimir Lazarevic13Jacques Schrenzel14Unit of Nutrition Geneva University Hospitals and University of Geneva Geneva SwitzerlandService of Nephrology University Hospitals of Lausanne and University of Lausanne Lausanne SwitzerlandService of Nephrology Cantonal Hospital of Sion Sion SwitzerlandService of Nephrology Cantonal Hospital of Sion Sion SwitzerlandLouvain Drug Research Institute, Metabolism and Nutrition Research Group, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO) Université catholique de Louvain Brussels BelgiumGenomic Research Lab and Service of Infectious Diseases Geneva University Hospitals and University of Geneva Geneva SwitzerlandDepartment of Rehabilitation and Geriatrics Geneva University Hospitals and University of Geneva Geneva SwitzerlandService of Nephrology Geneva University Hospitals and Clinique of Champel Geneva SwitzerlandUnit of Nutrition Geneva University Hospitals and University of Geneva Geneva SwitzerlandLouvain Drug Research Institute, Bioanalysis and Pharmacology of Bioactive Lipids Research Group Université catholique de Louvain Brussels BelgiumService of Nephrology Geneva University Hospitals and University of Geneva Geneva SwitzerlandLouvain Drug Research Institute, Metabolism and Nutrition Research Group, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO) Université catholique de Louvain Brussels BelgiumService of Nephrology University Hospitals of Lausanne and University of Lausanne Lausanne SwitzerlandGenomic Research Lab and Service of Infectious Diseases Geneva University Hospitals and University of Geneva Geneva SwitzerlandGenomic Research Lab and Service of Infectious Diseases Geneva University Hospitals and University of Geneva Geneva SwitzerlandAbstract Background We have previously shown that glycine increases fat‐free mass in chronic haemodialysis patients with features of malnutrition as compared with branched‐chain amino acids (BCAAs). This multicentre randomized double‐blind crossover study evaluates the impact of these amino acids on the gut barrier and microbiota. Methods Haemodialysis patients were included if they had plasma albumin <38 g/L or weight loss >5% of dry body weight, and daily dietary intakes <30 kcal/kg and <1 g protein/kg. They consumed glycine or BCAA (7 g twice daily) for 4 months and underwent a 1 month washout period, before crossover of supplementations. Faecal microbiota (16S rRNA gene sequencing) and immunoglobulin A (IgA), serum levels of cytokines, surrogate markers of intestinal permeability, appetite mediators, and endocannabinoids were obtained at the start and end of each supplementation. Supplementations were compared by multiple mixed linear regression models, adjusted for age, sex, month of supplementation (0 and 4 in each period), and period (Period 1: first 4 months; Period 2: last 4 months). Microbiota comparisons were performed using principal coordinate analysis and permutational multivariate analysis of variance, Shannon diversity index estimate and analysis of composition of microbiomes analysis, and Wilcoxon tests. Results We analysed 27 patients compliant to the supplementations. Multiple mixed linear regression models were significant only for interleukin‐6 (P = 0.002), glucagon‐like peptide 1 (P = 0.028), cholecystokinin (P = 0.021), and peptide YY (P = 0.002), but not for the other outcomes. The significant models did not show any impact of the type of supplementation (P < 0.05 in all models). Principal coordinate analysis and permutational multivariate analysis of variance (P = 0.0001) showed strong microbiota clustering by subject, but no effect of the amino acids. Bacterial alpha diversity and zero‐radius operational taxonomic unit richness remained stable, whatever the supplementation. Lacticaseibacillus paracasei (0.030; Q1–Q3 0.008–0.078 vs. 0.004; Q1–Q3 0.001–0.070) and Bifidobacterium dentium (0.0247; Q1–Q3 0.002–0.191 vs. 0.003; Q1–Q3 0.001–0.086) significantly decreased with the BCAA supplementation. Conclusions The BCAA and glycine supplementations had no impact on the serum levels of cytokines, appetite mediators, intestinal permeability, endocannabinoids, or faecal IgA. Overall faecal microbiota composition and microbial diversity did not change with the glycine or BCAA supplementation but decreased the abundance of L. paracasei and B. dentium.https://doi.org/10.1002/jcsm.12781Gut microbiotaGlycineBranched‐chain amino acid malnutritionEndocannabinoidsAppetite |
| spellingShingle | Laurence Genton Menno Pruijm Daniel Teta Isabelle Bassi Patrice D. Cani Nadia Gaïa François R. Herrmann Nicola Marangon Julie Mareschal Giulio G. Muccioli Catherine Stoermann Francesco Suriano Arlene Wurzner‐Ghajarzadeh Vladimir Lazarevic Jacques Schrenzel Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients Journal of Cachexia, Sarcopenia and Muscle Gut microbiota Glycine Branched‐chain amino acid malnutrition Endocannabinoids Appetite |
| title | Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients |
| title_full | Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients |
| title_fullStr | Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients |
| title_full_unstemmed | Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients |
| title_short | Gut barrier and microbiota changes with glycine and branched‐chain amino acid supplementation in chronic haemodialysis patients |
| title_sort | gut barrier and microbiota changes with glycine and branched chain amino acid supplementation in chronic haemodialysis patients |
| topic | Gut microbiota Glycine Branched‐chain amino acid malnutrition Endocannabinoids Appetite |
| url | https://doi.org/10.1002/jcsm.12781 |
| work_keys_str_mv | AT laurencegenton gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT mennopruijm gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT danielteta gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT isabellebassi gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT patricedcani gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT nadiagaia gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT francoisrherrmann gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT nicolamarangon gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT juliemareschal gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT giuliogmuccioli gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT catherinestoermann gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT francescosuriano gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT arlenewurznerghajarzadeh gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT vladimirlazarevic gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients AT jacquesschrenzel gutbarrierandmicrobiotachangeswithglycineandbranchedchainaminoacidsupplementationinchronichaemodialysispatients |